0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Response to Treatment with the Leukocyte-derived Immunomodulator IMREG-1 in Immunocompromised Patients with AIDS-related Complex: A Multicenter, Double-Blind, Placebo-Controlled Trial

Marise S. Gottlieb, MD; Robert A. Zackin, ScB; Milan Fiala, MD; David H. Henry, MD; Adrien J. Marcel, MD; Kenneth L. Combs, MD; Jeffrey Vieira, MD; Howard A. Liebman, MD; Lawrence A. Cone, MD; Kathryn S. Hillman, BA; and A. Arthur Gottlieb, MD
[+] Article and Author Information

Grant Support: In part by contracts from Imreg, Inc.

Requests for Reprints: Marise S. Gottlieb, MD, Imreg, Inc., One Kendall Square, Building 400, Cambridge, MA 02139.

Current Author Addresses: Drs. Gottlieb and Gottlieb and Mr. Zackin and Ms. Hillman: Imreg, Inc., One Kendall Square, Building 400, Cambridge, MA 02139.

Dr. Fiala: Eisenhower Medical Center, 39000 Bob Hope Drive, Kiewit Building, Suite 402, Rancho Mirage, CA 92270.

Dr. Henry: Graduate Hospital, Pepper Pavilion, Suite 505, 19th and Lombard Streets, Philadelphia, PA 19146.

Dr. Marcel: Community Research Initiatives, 31 West 26th Street, New York, NY 10010.

Dr. Combs: 501 Frenchmen Street, New Orleans, LA 70116.

Dr. Vieira: The Brooklyn-Caledonian Hospital, 121 DeKalb Avenue, Brooklyn, NY 11201.

Dr. Liebman: Boston City Hospital, 818 Harrison Avenue, Boston, MA 02118.

Dr. Cone: Eisenhower Medical Center, Probst Professional Building, Suite 308, 39000 Bob Hope Drive, Rancho Mirage, CA 92270.


©1991 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1991;115(2):84-91. doi:10.7326/0003-4819-115-2-84
Text Size: A A A

Objective: To determine if a 6-month course of therapy with IMREG-1, a leukocyte-derived immunomodulator, slows disease progression in patients with AIDS-related complex.

Design: Randomized, double-blind trial.

Setting: Five academic- and three community-based clinics.

Patients: Immunocompromised patients (143) with HIV.

Interventions: IMREG-1 or placebo every 2 weeks (13 doses).

Main Results: Twelve of forty-eight patients on placebo and 5 of 95 patients on IMREG-1 experienced adverse events (AIDS-defining opportunistic infection or neoplasm, wasting syndrome, HIV-associated encephalopathy, or peripheral sensory neuropathy). Based on an intention-to-treat analysis, Kaplan-Meier event probabilities were 26% for the placebo group and 6% for the IMREG-1 group (P < 0.001); based on the Cox proportional hazards model, the relative risk for patients on placebo compared with patients on IMREG-1 was 5.1 (95% Cl, 1.8 to 14.8). The frequency of symptoms significantly increased from baseline in patients receiving placebo. The mean decrease in CD4+ cells from baseline was 80 X 106 cells/L in the placebo group and 29 X 106 cells/L in patients on IMREG-1, with 20% (8) and 38% (32) of patients, respectively, showing a trend toward an increase (P = 0.04). In patients receiving IMREG-1, the size and rate of delayed hypersensitivity responses were larger than in the placebo group.

Conclusions: Patients with AIDS-related complex experienced fewer adverse events and constitutional symptoms after IMREG-1 treatment. The slower loss of CD4+ cells and increased size and rate of delayed hypersensitivity responses most likely reflect the effect of IMREG-1 on the immune system. No toxicity related to IMREG-1 administration was observed.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)